Plotnick L H, Ducharme F M
The Montreal Childrens' Hospital, Room C538E, 2300 Tupper Street, Montreal, Quebec, Canada, H3H 1P3.
Cochrane Database Syst Rev. 2000(2):CD000060. doi: 10.1002/14651858.CD000060.
Anti-cholinergic agents and beta2-agonist drugs are both bronchodilators used to reverse acute bronchospasm in children with asthma. These drugs have different modes of action, so may have complementary or additive effects.
The objective of this review was to assess the effects of adding inhaled anti-cholinergics to beta2-agonists in acute paediatric asthma.
We searched Medline (1966 to 1996), Embase (1980 to 1995), Cinahl (1982 to 1995) and reference lists of studies. We also contacted drug manufacturers and researchers.
Randomised trials comparing the combination of inhaled anti-cholinergics and beta2-agonists with beta2-agonists alone in children aged 18 months to 17 years with acute asthma.
Assessments of trial quality and data extraction were done by two reviewers independently.
Ten trials involving a total of 836 children were included. Most trials were of high quality. When only one dose of anti-cholinergic inhalation was added to beta2-agonist therapy, there was an improvement in forced expiratory volume in one second after 60 minutes with combination therapy (weighted mean difference 16.1%, 95% confidence interval 5.5 to 26. 7% reduction). There was no reduction in hospital admission (odds ratio 0.80, 95% confidence interval 0.35 to 1.82, using a random effects model). For multiple doses in children with severe asthma, there was a reduction in forced expiratory volume in 1 second (weighted mean difference 9.8% predicted, 95% confidence interval 6. 5 to 13.1% predicted). There may also be a reduction in hospital admission (odds ratio 0.62, 95% confidence interval 0.38 to 0.99). Eleven children would need to be given multiple doses of anti-cholinergics in combination with beta2-agonists to avoid one hospital admission compared to children given beta2-agonists alone.
REVIEWER'S CONCLUSIONS: In children with acute asthma, the addition of multiple doses of anti-cholinergics to inhaled beta2-agonists appears to improve lung function modestly and may decrease hospital admission. There is no associated increase in adverse effects. Single doses of anti-cholinergics may improve lung function in children with severe asthma, but do not appear to reduce hospital admissions.
抗胆碱能药物和β2受体激动剂都是用于缓解哮喘儿童急性支气管痉挛的支气管扩张剂。这些药物作用方式不同,因此可能具有互补或相加作用。
本综述的目的是评估在急性小儿哮喘中,吸入性抗胆碱能药物与β2受体激动剂联合使用的效果。
我们检索了Medline(1966年至1996年)、Embase(1980年至1995年)、Cinahl(1982年至1995年)以及相关研究的参考文献列表。我们还联系了药品制造商和研究人员。
比较18个月至17岁急性哮喘儿童吸入性抗胆碱能药物与β2受体激动剂联合使用和单独使用β2受体激动剂的随机试验。
两名评价者独立进行试验质量评估和数据提取。
纳入了10项试验,共涉及836名儿童。大多数试验质量较高。当在β2受体激动剂治疗中仅添加一剂抗胆碱能吸入剂时,联合治疗60分钟后一秒用力呼气量有所改善(加权平均差16.1%,95%置信区间为降低5.5%至26.7%)。住院率没有降低(比值比0.80,95%置信区间0.35至1.82,采用随机效应模型)。对于重度哮喘儿童使用多剂药物时,一秒用力呼气量有所降低(加权平均差为预测值的9.8%,95%置信区间为预测值的6.5%至13.1%)。住院率可能也会降低(比值比0.62,95%置信区间0.38至0.99)。与仅接受β2受体激动剂治疗的儿童相比,每11名接受抗胆碱能药物与β2受体激动剂联合多剂治疗的儿童中,可有1名避免住院。
在急性哮喘儿童中,在吸入性β2受体激动剂基础上加用多剂抗胆碱能药物似乎能适度改善肺功能,并可能降低住院率。且未伴随不良反应增加。单剂抗胆碱能药物可能改善重度哮喘儿童的肺功能,但似乎不能降低住院率。